Author of Quantitative Investing, the Quantitative Risk & Value letter and the free Market Timing Signals. Often in the SeekingAlpha top 5 on Portfolio Strategy. Available model portfolios: market neutral, growth, closed-end funds, Vix trading. For more information, click "send message".
PhD, Software Engineer, Civil Engineer, 20+ years working in various sectors and countries. Also a lifelong rock climber and ex ski-mountaineering racer.
Ian’s Insider Corner research focuses primarily on long-term dividend-paying companies with stable and reliable growth, stocks suitable for individual retirement accounts. Ian also looks for “niche” shorter-term trading opportunities, and coverage. During the 3-years Ian worked at Kerrisdale Capital, the New York-based activist hedge fund had great success exposing fraudulent companies. Kerrisdale Capital returned almost 200% in 2011, and more than 300% in total. Ian Bezek offers in-depth coverage of all the stocks in his “IMF” portfolio.
Ever feel like trading is like rolling dice? In a way, it is, because every mathematical model of the market includes a stochastic aspect. But I believe we can load the dice in our favor through the use of statistics. Understanding both the stock market and each individual stock as a sort of random process with its own characteristics allows us to more accurately predict what it will do in the future. Coupling statistics with fundamental analysis, I have the goal of revealing to you the hidden patterns within stocks so that you may do what you wish with that information.
I have been an Analyst on both the Buyside and Sellside. In addition, I have worked in a Corporate Strategy and Finance role for technology services companies. For many years I've been building quantitative models to create risk-adjusted, return-driven products for DIY individual investors through our platform Graycell Advisors. Our biotech related product - The Prudent Biotech Portfolio - is a quantitative-driven systematic investing product.
For the year 2016, the Prudent Biotech Portfolio was up +7%, compared to IBB (representing Nasdaq Biotech Index) decline of -21%. In addition, the Graycell Smallcap Portfolio was up +71% compared to benchmark Russell 2000 Index gain of +19%.
We invite you to take a look at the Graycell Advisors and Prudent Biotech websites for Performance, Philosophy, and Approach, and decide for yourself if the Biotech and Small Cap products can contribute to your investment objectives.
You can even view Samples, Register for a Free Pick from the Portfolio, and also check the Risk-free Subscription with a 60-day Money-back Guarantee.
Nothing here or on the site constitutes a personalized investment recommendation, and stocks mentioned in the reports/articles/comments may be now or in the past, part of the portfolios recommended by Graycell Advisors and related entities. Graycell Advisors and related entities are not a Registered Investment Advisor (RIA).
Any questions, please write to Support @ PrudentBiotech.com
W. (Ed) Wijaranakula has been a portfolio manager for over 15 years. He has a Ph.D. in Electronic Materials and has worked with Intel, Taiwan Semiconductor, Texas Instruments, and other tech companies in the Silicon Valley, during his professional career. He was also involved with industry research projects at MIT, NC State and the University of Washington. His investment research expertise includes biotech, commodities and currencies. He has published over 700 articles and holds 14 U.S. and international patents.
Investor since a decade, who invests cent percent of investment capital into equities and does his own research to chose long term winners, who will also be a decent bet for the medium term.
I manage the following, where you can follow me and interact at (free forever):
i. A Facebook page which conveys relevant business news, market information, views and insights ( facebook.com/WallStreetGuru )
ii. A Twitter handle where I share my picks, offer 'blatant' view on market events and answer questions: @ABraveBull
iii. A blog that I write on significant market events (http://www.sunnygoklani.com/brave-bull-updates).
I believe knowledge is cumulative and everyone has a unique contribution to make. We all collectively make this world a better place to co-exist.
Founder of stockoptionsdad.com - a venue created to share investing ideas and strategies with an emphasis on options trading. My aim is to empower investors and traders alike to leverage options trading as part of an overall investment strategy. I am a leading author and contributor on several crowdsourced financial websites, namely Seeking Alpha and INO.com. I cover a broad range of investment strategies; currency hedging, value, growth, options and dividend investing. I also cover long-term wealth creating strategies such as leveraging 401ks, Roth IRAs, 529 College Accounts and Health Savings Accounts (HSAs) to augment one's long-term investment approach. My area of emphasis is geared towards the overall healthcare industry (i.e. biotechnology, health insurers, large pharma, pharmacy benefit managers and pharmaceutical wholesalers) highlighting sector trends, political backdrop/current events, key developments and mergers and acquisitions. I am a biotechnology professional with a diverse scientific background and detailed knowledge in many therapeutic areas such as monoclonal antibodies and immunotherapies. I have a deep understanding of the clinical and regulatory aspects with respect to drug development and drug approvals. I have a personal interest in finance, investing and specifically options trading. My investment strategy is long-term/retirement oriented while exploring avenues to maximize wealth in retirement. My analyses are focused on individual stocks, sector trends and niche opportunities such as options trading.
Project Management Certification in Biotechnology
Masters of Science in Molecular and Cellular Biology
Bachelor of Science in Biological Sciences
Professional investor and overall good guy.
By reading Mako Research reports, you agree to use the information at your own risk. In no event should Mako Research or any affiliated party be liable for any direct or indirect trading losses caused by information contained in the research reports. Research reports are not investment advice or a recommendation or solicitation to transact any securities. Mako Research is not a registered investment advisor. You agree to do your own research and due diligence before making any investment decision with respect to securities covered herein. You should assume that Mako Research stands to profit in the event the issuer’s stock declines. Research reports may contain opinions, which are based upon generally available public information, field research, inferences and deductions through due diligence and analytical processes. All information is believed to be accurate and reliable, and has been obtained from public sources. Mako Research makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information. All expressions of opinion are subject to change without notice, and Mako Research is not obligated to update or supplement any reports or any of the information, analysis and opinion contained in them. You should assume that Mako Research has and/or will submit findings with the Securities Exchange Commission, and other entities that may find the information useful.
Steven Bulwa is an investment analyst with a focus on new developments in science, technology and medicine and the companies poised to benefit. He has contributed to TheStreet.com, Realmoney.com and SeekingAlpha.com, BusinessInsider.com, Mediaite.com and HuffingtonPost.com among others. Steven has actively followed developments in technology for over 20 years, working with a scientific advisory board to validate potential investments. Early in his career, as a musician and recording engineer, Steven recognized the importance of the shift from analog to digital recording. This inspired his first stock investment in a company providing hardware and software solutions to television news providers converting to a digital video environment. The success of this investment inspired Steven to continue to delve into yet-to-be recognized investment opportunities in technology. While writing for thestreet.com in 2006, Steven was one of the first analysts to identify the explosive investment opportunity of 3D Printing. At the time he wrote articles about Stratasys(SSYS) and 3D Systems(DDD). Steven's picks like Nuvasive(NUVA) were also featured on Jim Cramer's Mad Money on CNBC. He has also acted as a consultant to companies looking to acquire new technologies including nanotechnology.
A practical investor, Steven also called the demise of the housing and mortgage markets after listening to one of Ben Bernanke’s early testimonies while simultaneously learning of Bank of America’s efforts to proactively renegotiate troubled home loans. In our capitalist economy, companies only renegotiate out of desperation, trouble was obviously coming!
Technology now evolves so rapidly that there are always great new technology companies with tremendous growth potential to invest in. Big cap tech's strongest growth is past, Steve wants to help you invest in tomorrow’s Apple,Google, or Microsoft.
I am Semi-retired as a consultant (40+ years) in the fields of applied Pharmacology/Toxicology and Occupational Health & Safety, dealing with the role of drugs and chemicals in disease pathology and its treatment, complex exposure situations (use of medications, drugs of abuse & addiction and exposure to toxic workplace chemicals), toxicity and drug/chemical interactions and related management challenges.
I am now delving into the investment world for hobby and to increase retirement resources using my own capabilities and the many resources available. I am a novice investor and looking to learn at my pace and with assistance from others. I have strong scientific (pharmacology & health) and analytical training, experience and perspective. I have formal Risk Management training and experience and will use that to guide my investing decisions.
From an investment perspective, I am looking for a combination of stable and proven income generating companies, balanced with managed risk associated with biotechnology equities with large upside potential, ones leading the charge into research and development of ground breaking biological solutions to society' needs. I plan to focus on the biotechnology sector as that is where my strength lies. I look forward to learning from the SA contributors and where appropriate making a contribution with my perspective and views.
I am individual investor that has been investing for his retirement for the past 40 years. During that time I have had great successes and great losses but with each win and loss I have learned something about the market and the stock I own. I do not invest for a living as my real job is as a full time Plant Manager at a local manufacturing company that makes consumer products that ship worldwide. Investing is a serious hobby for me and I spend a lot of free time doing it. I know that my wife of 34 years would say that I spend to much time at it but we will both have the opportunity to appreciate my efforts in the years ahead.
I am a medical professional that enjoys investing in biotech stocks. I take long positions and may dabble in options. I have a particular interest in biotechs with an ophthalmic (eye) focus as that is where I have developed the greatest expertise over my career and research. I hope over time to share some of my professional insights with those of the Seeking Alpha community in order to help them make more informed investing decisions. I expect to learn a lot from others as well.
I am long the following biotechs at this time: GILD, OPHT, CRMD, ACAD, RLYP, HALO, TGTX, APHB, ZIOP.
I am advising everyone to avoid: OHRP
I have background in Electrical Engineering and value investing.
I write and read about finance as a hobby. The goal is to learn more, connect with like-minded people and share ideas.
Have a good one!
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a Technology Transfer Officer at UCLA. He has a B.S. from Penn State University and an MBA from Rutgers University.
His WEB site at www.raygent.com is currently focused in biopharmaceuticals, genomics and clinical diagnostics . Mr. Raynovich has extensive expertise in marketing and product development and provides business development consulting to early stage companies in biotechnology, diagnostics and imaging.
The Rayno Life Science Portfolio was published on www.raygent.com and other trade media.
Articles have been published on the following topics: Alzheimer Disease,Biomarkers, Genomics,Molecular Diagnostics, Oncology Drugs, Personalized Medicine, Targeted Therapy, Technology Trends, H1N1 and Government Policy on biotechnology.
The Life Science Portfolio is up over 80% over a 24 mo. period as of 5/30/14and among the life science portfolio winners are ABAX, ALXN, AMRI, BIIB, CBST, GPRO, ILMN, QDEL,REGN, SGEN, and VPHM.
Founder of Slingshot Insights, a company that works to provide retail investors access to professional grade investment research tools not readily at their disposal. As a former analyst at a large hedge fund, I found that as I began trading individual stocks on my own, I missed the research tools available to me when I worked for a large institution. The company was born from this idea and my desire to have access to a resource like SI.
www.SlingshotInsights.com Join for free today and check out our cartoon where "Investor Man" Becomes the Smart Money (and explains what Slingshot Insights can do for your diligence process)
Prior to starting Slingshot Insights, I was an analyst at a large hedge fund where I focused on the pharmaceutical industry creating investment theses driven by primary research. I remain a very active investor in a variety of stocks.
I am a Ph.D. level scientist at a major pharmaceutical company. Previously I was an NIH Cancer Postdoctoral fellow at UPENN. Through my extensive research background, I am able to quickly decipher clinical information and act on it. I specialize in analyzing and trading biotech/healthcare stocks both long and short. I maintain a few core positions and trade clinical events based on extensive research to realize large percentage gains. I am open to opportunities in consulting for financial firms or local advisors. Please contact me if you are interested.
I am the publisher of the Fundamental Trends Investment Letter and have over 20 years of experience as an investment advisor. I've been ranked a top analyst by TipRanks.com for my tracked public performance over the past five years.
Find me on MarketWatch where I was named Named "The World's Next Great Investing Columnist," Seeking Alpha, TheStreet.com, Morningstar, Real Clear Markets and numerous other sites. I have been a featured guest on the "Boomers Rock" radio show and appeared on Fox Business.
I'm from a middle class working family. I invest using a top down approach to find the best sectors, industries and regions and then a bottom up approach to find the best opportunities in those areas. I make extensive use of option selling to generate portfolio income, mitigate risk and build positions in assets I like intermediate term.
My goal is to help people find greater financial freedom.
Long/short biotech investment ideas with a focus on oncology/infectious disease/immunology.
Postings on this site are my own and do not represent the positions, strategies, or opinions of my employer.
An experienced research and advisory team of Traders and Forecasters have combined to offer free services and alerts at StockReversals.com, A free growth stock profile, research and alert service with benefits. Go to the website to subscribe for free. We also offer StockReversalsPremium.com which offers a combination of long term growth stock profiles with massive upside potential, plus swing position trading (days to 8 weeks holding).
Seeking Alpha Certified and Frequent Contributor to numerous financial websites. We specialize in behavioral analysis as it applies to market patterns and reversal trends. These trends happen over short term, intermediate, and long term time frames. We help our free subscribers with Business Disruptor growth stocks that crush the market. Sample picks include FB, YY, DATA, INVN, SPCB, MOBI, CUR and many more. In 6 months we had 6 doubles, 1 triple, and 16 of 19 companies up 30-50% or more.
Our work centers around a combination of Elliott Wave Theory, Technical Analysis, Human Behaviors, Sentiment, and Business Disruption analysis.
We have advisory clients from around the world. South Korea, Australia, Canada, Sweden, Germany, The Netherlands and of course the U.S.
We give away our service for free because of the laws of nature which we have on our website:
“The possession of knowledge, unless accompanied by the manifestation and expression in sharing is a vain and foolish thing. The Law of Use is universal, and he who violates it suffers by reason of his conflict with natural forces.”
Join us today at stockreversals.com and sign up for free.
6 years in investment banking at Bulge bracket, 2 years at Italian Bank, 1.5 year at Hedge Fund
Engineer, MBA, CFA Charterholder
10 years total in Financial markets
Currently managing personal assets: mainly biotech, banks, value stocks, event situations
As Managing Editor - Opinion and Analysis, I lead the Seeking Alpha team dedicated to curation of crowdsourced investment research and commentary. My responsibilities are to grow the site's audience, deepen user engagement, and improve editorial processes. I am a CFA charterholder and member of the CFA Society Washington, DC.
I have a B.S. in Chemical Engineering from the University of Maryland and have worked on FDA clinical trials in the medical device industry for the last 10 years. I have more than 25 years investing experience.
Spent my entire 28 year career on Wall Street with over a decade at Bear Stearns. No "Wall Street Titan" in real life but WST is an alias that I've used for years on Yahoo so I use it when I write on SA. I have gained a significant amount of knowledge regarding the stem cell sector over the years and have recently launched a premium service covering this exciting area.
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek, email him directly: firstname.lastname@example.org (mailto:email@example.com)